VT3989, a transcriptional enhanced associate domain autopalmitoylation inhibitor, targets the Hippo pathway in mesothelioma treatment. The FDA's fast track designation aims to expedite VT3989's ...
Researchers working independently at the University of Hawaii Cancer Center and the National Cancer Institute have discovered, and validated, a new variant of mesothelioma that may lead to more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results